Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CAPTOPRIL

All products: not a benefit

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Cilazapril (Inhibace): general benefit, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit
  • Perindopril erbumine (Coversyl): general benefit

3 more in the class list below

Capoten · DIN 00546305 · 100mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-02-05 — choose a marketed DIN from the same-category list.Discontinued 2008-02-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-02-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-02-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Capoten · DIN 00546305 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2008-02-05 · brand CAPOTEN TAB 100MG · ATC C09AA01 CAPTOPRIL · form Tablet · route Oral · ingredients CAPTOPRIL 100 MG · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Capoten: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4621 · Verify on the e-Formulary ↗ (DIN 00546305)

Source record
DIN 00546305: Capoten Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800076; group id 317; item number 0704; lccId None; manufacturer id BQU Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00546305 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4621
Interchangeable products
Apo-Capto · DIN 00893625 · $1.0395 Teva-Captopril · DIN 01942999 · $1.0395
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00546305
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2008-02-05 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 45 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

RAMIPRIL

· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: or renovascular hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ENALAPRIL MALEATE · Listed, not a benefit (1), General benefit (51)  essential or renovascular hypertension PM: https://pdf.hres.ca/dpd_pm/00061923.PDF; date not captured; DIN 00670901; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Hypertension APO-CAPTO (captopril) is indicated for the treatment of essential or renovascular hypertension. It is usually administered in association with other drugs, particularly thiazide diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. In using APO-CAPTO, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). a) In patients with normal renal function. APO-CAPTO should normally be used in those patients in whom treatment with diuretics or beta-blockers was found ineffective or has been associated with unacceptable adverse effects. APO-CAPTO can be tried as an initial agent in those patients with severe hypertension or in those in whom the use of diuretics and/or beta-blockers is contraindicated or in patients with medical conditions in which those drugs frequently cause serious adverse effects. b) In patients with impaired renal function. In these patients, particularly those with collagen vascular disease, captopril should be reserved for hypertensives wh… https://pdf.hres.ca/dpd_pm/00022606.PDF PM date: November 1, 2013 Source product: APO-CAPTO TAB 12.5MG; DIN 00893595; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Capoten: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026